Roche’s Herceptin Heart Risk Higher for Older Women, Study Says

Roche Holding AG (ROG)’s cancer drug Herceptin poses a bigger risk of heart problems for elderly patients than for the younger women usually recruited in clinical trials, researchers said in a study published today in the journal Annals of Oncology.

The study reviewed records for 45 women between the ages of 70 and 92, and it’s the first to assess the Roche drug’s heart risks specifically for elderly patients, researchers said.

To contact the reporter on this story: Naomi Kresge in Zurich at

To contact the editor responsible for this story: Phil Serafino at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.